Drug Profile
PD 360324
Alternative Names: PD-0360324; PD-360,324Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Macrophage colony stimulating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Discontinued Cutaneous lupus erythematosus; Pulmonary sarcoidosis; Rheumatoid arthritis
Most Recent Events
- 30 Nov 2022 Phase-II development in Solid tumours is ongoing in USA, Australia, Canada, France, Japan, Poland, Taiwan, and United Kingdom (NCT02554812)
- 28 Sep 2021 Pfizer plans a phase III trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Japan (PO) (NCT05059522)
- 09 Jan 2020 PD 360324 is still in phase II trials for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA, United Kingdom, Australia, Canada, France, Germany, Netherlands, Japan (IV) (NCT02554812) (EudraCT2015-002552-27)